Role of polysomy 17 in transitional cell carcinoma of the bladder: Immunohistochemical study of HER2/neu expression and FISH analysis of c-erbB-2 gene and chromosome 17

International Journal of Surgical Pathology

Volumn 17, Issue 3, 2009, Pages 198-205

  Simonetti, Sara ^a   Russo, Rosa ^b   Ciancia, Giuseppe ^a   Altieri, Vincenzo ^a   De Rosa, Gaetano ^a,c   Insabato, Luigi ^a  

^a University on Naples   (Italy)

^b Ospedale S Leonardo   (Italy)

^c Regional Oncologic Hospital   (Italy)

Author keywords

Chromosome 17; FISH analysis; HER2; Neu; Polysomy; Transitional cell carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER INVASION; CANCER PATIENT; CHROMOSOME 17; CHROMOSOME ABERRATION; CHROMOSOME NUMBER; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DUPLICATION; GENE NUMBER; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, ERBB-2; URINARY BLADDER NEOPLASMS;

EID: 65849287224     PISSN: 10668969     EISSN: None     Source Type: Journal    
DOI: 10.1177/1066896909333415     Document Type: Article

References (33)

1. Baffa R., Letko J., McClung C., LeNoir J., Vecchione A., Gomella LG Molecular genetics of bladder cancer: targets for diagnosis and therapy. J Exp Clin Cancer Res. 2006 ; 25: 145-160.
2. Fradet Y., Lacombe L. Can biological markers predict recurrence and progression of superficial bladder cancer ? Curr Opin Urol. 2000 ; 10: 41-45.
3. Hauser-Kronberger C., Peham K., Grall J., Rausch W., Hutarew G., Dietze O. Novel approach of human epidermal growth factor receptor 2 detection in noninvasive and invasive transitional cell carcinoma of the bladder. J Urol. 2006 ; 175: 875-880.
4. Sauter G., Moch H., Moore D., et al. Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res. 1993 ; 53: 2199-2203.
5. Langner C., Gross C., Rehak P., Ratschek M., Rüschoff J., Zigeuner R. HER2/neu protein overexpression and gene amplification in upper urinary tract transitional cell carcinoma: systematic analysis applying tissue microarray technique. Urology. 2005 ; 65: 176-180.
6. Olayioye MA, Beuvink I., Horsch K., Daly JM, Hynes NE ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem. 1999 ; 274: 17209-17218.
7. Olayioye MA, Neve RM, Lane HA, Hynes NE The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000 ; 19: 3159-3167.
8. Giltnane JM, Murren JR, Rimm DL, King BL AQUA and FISH analysis of IHC expression and amplification in a small cell lung carcinoma tissue microarray. Histopathology. 2006 ; 49: 161-169.
9. Kanta SY, Yamane T., Dobashi Y., Mitsui F., Kono K., Ooi A. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2/neu gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Hum Pathol. 2006 ; 37: 1333-1343.
10. Shiga H., Rasmussen AA, Johnston PG, et al. Prognostic value of c-erbB2 and other markers in patients treated with chemotherapy for recurrent head and neck cancer. Head Neck. 2000 ; 22: 599-608.
11. Gullick WJ The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast cancer. Int J Cancer Suppl. 1990 ; 5: 55-61.
12. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin. 2008 ; 58: 71-96.
13. Thrasher JB, Crawford ED Current management of invasive and metastatic transitional cell carcinoma of the bladder. J Urol. 1993 ; 149: 957-972.
14. Trkova M., Babjuk M., Duskova J., et al. Analysis of genetic events in 17p13 and 9p21 regions supports predominant monoclonal origin of multifocal and recurrent bladder cancer. Cancer Lett. 2006 ; 242: 68-76.
15. Edwards J., Duncan P., Going JJ, Grigor KM, Watters AD, Bartlett JM Loss of heterozygosity on chromosomes 11 and 17 are markers of recurrence in TCC of the bladder. Br J Cancer. 2001 ; 85: 1894-1899.
16. Watters AD, Ballantyne SA, Going JJ, Grigor KM, Bartlett JM Aneusomy of chromosomes 7 and 17 predicts the recurrence of transitional cell carcinoma of the urinary bladder. BJU Int. 2000 ; 85: 42-47.
17. Watters AD, Going JJ, Cooke TG, Bartlett JM Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat. 2003 ; 77: 109-114.
18. Watters AD, Going JJ, Grigor KM, Bartlett JM Progression to detrusor-muscle invasion in bladder carcinoma is associated with polysomy of chromosomes 1 and 8 in recurrent pTa/pT1 tumours. Eur J Cancer. 2002 ; 38: 1593-1599.
19. Latif Z., Watters AD, Dunn I., Grigor K., Underwood MA, Bartlett JM HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2/neu therapy ? Eur J Cancer. 2004 ; 40: 56-63.
20. Latif Z., Watters AD, Dunn I., Grigor KM, Underwood MA, Bartlett JM HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer. 2003 ; 89: 1305-1309.
21. Ohta JI, Miyoshi Y., Uemura H., et al. Fluorescence in situ hybridization evaluation of c-erbB-2 gene amplification and chromosomal anomalies in bladder cancer. Clin Cancer Res. 2001 ; 7: 2463-2467.
22. Wang S., Hossein Saboorian M., Frenkel EP, et al. Aneusomy 17 in breast cancer: its role in IHC protein expression and implication for clinical assessment of IHC status. Mod Pathol. 2002 ; 15: 137-145.
23. Gullo G., Bettio D., Torri V., Masci G., Salvini P., Santoro A. Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2/neu-positive metastatic breast cancer [published online ahead of print July 29, 2008]. Invest New Drugs. doi:10.1007/s10637-008-9155-y.
24. Matsubara H., Yamada Y., Naruse K., et al. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization. Oncol Rep. 2008 ; 19: 57-63.
25. Zhau HE, Zhang X., von Eschenbach AC, et al. Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer. Mol Carcinog. 1990 ; 3: 254-257.
26. Mellon JK, Lunec J., Wright C., Horne CH, Kelly P., Neal DE C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol. 1996 ; 155: 321-326.
27. Underwood M., Bartlett J., Reeves J., Gardiner DS, Scott R., Cooke T. C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors ? Cancer Res. 1995 ; 55: 2422-2430.
28. Caner V., Turk NS, Duzcan F., et al. No strong association between IHC protein overexpression and gene amplification in high-grade invasive urothelial carcinomas. Pathol Oncol Res. 2008 ; 14: 261-266.
29. Shiga K., Shiga C., Sasano H., et al. Expression of c-erbB-2 in human esophageal carcinoma cells: overexpression correlated with gene amplification or with GATA-3 transcription factor expression. Anticancer Res. 1993 ; 13: 1293-1301.
30. Hollywood DP, Hurst HC Targeting gene transcription: a new strategy to down-regulate c-erbB-2 expression in mammary carcinoma. Br J Cancer. 1995 ; 71: 753-757.
31. Ribal MJ, Alcaraz A., Mengual L., et al. Chromosomal high-polysomies predict tumour progression in T1 transitional cell carcinoma of the bladder. Eur Urol. 2004 ; 45: 593-599.
32. Krüger S., Mess F., Böhle A., Feller AC Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder. Int J Oncol. 2003 ; 23: 41-48.
33. Leonardo C., Merola R., Orlandi G., Leonardo F., Rondoni M., De Nunzio C. C-erb-2 gene amplification and chromosomal anomalies in bladder cancer: preliminary results. J Exp Clin Cancer Res. 2005 ; 24: 633-638.